Home › Funds › PFM Health Sciences, LP › EPRX
PFM Health Sciences, LP position in EPRX
EUPRAXIA PHARMACEUTICALS INC · Health Care
PFM Health Sciences, LP reported holding 1,210,661 shares of EPRX (EUPRAXIA PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$8.0M, representing 0.70% of its reported portfolio and ranking #49 among its reported holdings. PFM Health Sciences, LP has disclosed EPRX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How PFM Health Sciences, LP's EPRX position evolved
PFM Health Sciences, LP first disclosed a stake in EPRX in Q1 2026 at 540,871 shares (US$3.9M). The position peaked in Q2 2026 at 1,210,661 shares, worth US$8.0M. Across 2 filings, PFM Health Sciences, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,210,661 shares valued at US$8.0M — an increase of 669,790 shares quarter over quarter.. Notable position changes include a 124% increase in Q2 2026 (shares rose 38% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 540.87K | $3.92M | New |
| Q2 2026 | 1.21M | $8.00M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EPRX and 13F data
EPRX (EUPRAXIA PHARMACEUTICALS INC) is a Health Care company. 69 other funds we track also report a position in EPRX — the largest reported positions include Vivo Capital, LLC (US$8.9M), GREAT POINT PARTNERS LLC (US$7.9M), Ikarian Capital, LLC (US$5.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EPRX
- Vivo Capital, LLC 1.35M sh · $8.92M · Q2 2026
- GREAT POINT PARTNERS LLC 1.20M sh · $7.93M · Q2 2026
- Ikarian Capital, LLC 809.74K sh · $5.35M · Q2 2026
- Redmile Group, LLC 611.40K sh · $4.04M · Q2 2026
- Seven Fleet Capital Management LP 610.78K sh · $4.04M · Q2 2026
- Velan Capital Investment Management LP 352.00K sh · $2.33M · Q2 2026
- Aisling Capital Management LP 325.00K sh · $2.15M · Q2 2026
- Ally Bridge Group (NY) LLC 252.18K sh · $1.67M · Q2 2026
- Delaney Capital Management Ltd. 117.20K sh · $767.86K · Q2 2026
- Lynx1 Capital Management LP 10.00K sh · $66.10K · Q2 2026
More on PFM Health Sciences, LP
FAQ
How long has PFM Health Sciences, LP held EPRX?
PFM Health Sciences, LP has disclosed EPRX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is PFM Health Sciences, LP's current position in EPRX?
As of Q2 2026, PFM Health Sciences, LP holds 1.21M shares of EPRX (EUPRAXIA PHARMACEUTICALS INC), valued at $8.00M, representing 0.70% of its reported portfolio and ranking #49.
Has PFM Health Sciences, LP been buying or selling EPRX?
In the latest 13F filing (Q2 2026), PFM Health Sciences, LP increased its position in EPRX. The position peaked in Q2 2026 at 1.21M shares.
Which other funds hold EPRX?
Other major institutional holders of EPRX include Vivo Capital, LLC, GREAT POINT PARTNERS LLC, Ikarian Capital, LLC, among 69 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.